BCIQ Profiles

Company Profile Report

Phase II data show Novo’s semaglutide leads the pack on NASH resolution

Novo Nordisk disclosed top-line Phase II data in NASH for semaglutide that puts the GLP-1 agonist in pole position with respect to mechanisms addressing NASH resolution.

The readout came as Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) announced strong growth in 1Q20 due to COVID-19-related stockpiling.

Novo said

Read the full 474 word article

How to gain access

Continue reading with a
two-week free trial.